Company intelligence / Profile preview

BioMendics

Rootstown, Ohio, United Statesbiomendics.com ↗

Ownership: Private
Development stage: Phase 2

Overview

BioMendics completed their TAMES Phase I/IIa study with Stanford Medicine, Dermatology in summer 2023 in patients with severe EBS. The company received Orphan Drug Designation on May 1, 2023, for their proprietary molecule, BM-3103, and has Rare Pediatric Disease designation for BM-3103 from February 2021. They are planning a Phase II study (TAMES-02) in 2024[6][7].

Therapeutic areas: DermatologyRheumatology
Modalities: Small molecule liquid crystalsmTOR inhibitors
Industry: Biotech

Drug pipeline

2 assets

TolaSure Vehicle Gel

1 more asset in the full pipeline.

Request access →

Partnerships

Stanford Medicine, Dermatology

Beyond the preview

Go deeper on BioMendics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BioMendics.

Explore the full profile